Kezar Life Sciences, Inc.KZRNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune.

zacks.com

Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

defenseworld.net

Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Recommendation of “Reduce” from Brokerages

Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have received an average recommendation of "Reduce" from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The

defenseworld.net

Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)

Dyadic International (NASDAQ: DYAI - Get Free Report) and Kezar Life Sciences (NASDAQ: KZR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation. Profitability This table compares Dyadic International

businesswire.com

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunopro.

businesswire.com

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the completed Phase 2a PORTOLA clinical trial in patients with autoimmune hepatitis (AIH) at The Liver Meeting 2025 held by the American Association for the Study of Liver Disease (AASLD) and taking place November 7-11, in Washington, DC.

businesswire.com

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced regulatory updates and the initiation of a process to explore a full range of strategic alternatives focused on maximizing shareholder value. The Company has retained TD Cowen to support it with the strategic review process. Kezar has been unable to.

zacks.com

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

businesswire.com

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis,” said Chris Kirk, PhD, CEO and co-founder of Keza.

businesswire.com

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in.

businesswire.com

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the “Even.

zacks.com

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

businesswire.com

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH,” said Chris Kirk, CEO and co-founder.

seekingalpha.com

Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & Co-Founder Dr. Craig Lammert - Principal Investigator of PORTOLA Study Gideon Hirschfield - Professor University of Toronto, Autoimmune Liver Disease Research Conference Call Participants Matt Phipps - William Blair Divya Rao - TD Cowen Maury Raycroft - Jefferies Derek Archila - Wells Fargo Mitchell Kapoor - H.C. Wainwright Operator Good day, everyone.

businesswire.com

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH) and reported fourth quarter and year end 2024 financial results. “.

businesswire.com

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA tri.

businesswire.com

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025,”.

businesswire.com

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors' and officers' possible violations of state laws. If you own Kezar Life Sciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance